Link to this page
National Cancer Institute Thesaurus
Last uploaded:
February 23, 2024
Jump to:
| Id | http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1051
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1051
|
|---|---|
| Preferred Name | Cilostazol |
| Definitions |
A quinolinone derivative and cellular phosphodiesterase inhibitor, more specific for phosphodiesterase III (PDE III). Although the exact mechanism of action of is unknown, cilostazol and its metabolites appears to inhibit PDE III activity, thereby suppressing cyclic adenosine monophosphate (cAMP) degradation. This results in an increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.
|
| Synonyms |
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
CILOSTAZOL
Cilostazol
Pletal
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| label |
Cilostazol
|
|---|---|
| Legacy Concept Name |
Cilostazol
|
| CHEBI_ID |
CHEBI:31401
|
| Preferred_Name |
Cilostazol
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| prefixIRI |
Thesaurus:C1051
|
| DEFINITION |
A quinolinone derivative and cellular phosphodiesterase inhibitor, more specific for phosphodiesterase III (PDE III). Although the exact mechanism of action of is unknown, cilostazol and its metabolites appears to inhibit PDE III activity, thereby suppressing cyclic adenosine monophosphate (cAMP) degradation. This results in an increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.
|
| UMLS_CUI |
C0055729
|
| code |
C1051
|
| Chemical_Formula |
C20H27N5O2
|
| subClassOf | |
| type | |
| CAS_Registry |
73963-72-1
|
| FULL_SYN |
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
CILOSTAZOL
Cilostazol
Pletal
|
| FDA_UNII_Code |
N7Z035406B
|
| Contributing_Source |
FDA
HemOnc
|
| Concept_In_Subset |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |